Nature Communications (Jul 2018)

In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer

  • Caitlin L. Grzeskowiak,
  • Samrat T. Kundu,
  • Xiulei Mo,
  • Andrei A. Ivanov,
  • Oksana Zagorodna,
  • Hengyu Lu,
  • Richard H. Chapple,
  • Yiu Huen Tsang,
  • Daniela Moreno,
  • Maribel Mosqueda,
  • Karina Eterovic,
  • Jared J. Fradette,
  • Sumreen Ahmad,
  • Fengju Chen,
  • Zechen Chong,
  • Ken Chen,
  • Chad J. Creighton,
  • Haian Fu,
  • Gordon B. Mills,
  • Don L. Gibbons,
  • Kenneth L. Scott

DOI
https://doi.org/10.1038/s41467-018-04572-3
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 13

Abstract

Read online

KRAS-driven lung cancers represent an aggressive form of NSCLC. In this study the authors perform an in vivo functional screening and identify GATAD2B as a driver of tumor growth and metastasis in KRAS-driven lung cancer.